Citation

Ceresér KMM, Mascarenhas M, Santin A, Kapczinski F. Br. J. Pharm. Sci. 2009; 45(2): 249-256.

Copyright

(Copyright © 2009, Universidade de São Paulo, Faculdade de Ciências Farmacêuticas)

DOI

10.1590/S1984-82502009000200009

PMID

unavailable

Abstract

The Bipolar Mood Disorder is characterized by the alternation of depressive crises with episodes of mania or euphoria, having these patients 15 to 35 times more chances of suicide, as compared with people without this disorder. The pharmacotherapy is fundamental for this disease, aiming to decrease the frequency of episodes and disease severity. In these patients, the polypharmacy has recently increased and one of the main difficulties is the adherence to treatment. The objective of this study was to contribute for the improvement of bipolar patients health conditions, developing their respective pharmacotherapeutic follow-up. Twenty eight adult bipolar patients who were participants of a specialized clinic within a tertiary hospital in Porto Alegre have been randomly selected, and the Dader Method of pharmacotherapeutic follow-up has been applied. The more common clinical comorbidities were: hypertension (50%), obesity (46.43%), and hypothyroidism (36.29%). The bipolar patients are more susceptible to clinical comorbidities, and many of them could be due to pharmacotherapy. Only 1.43% of patients presented Drug Related Problems, being all of them resolved along the study. It was also observed that 32.14% of evaluated patients presented low adherence to treatment, and between these patients, 55.56% passed to have good adherence after pharmacotherapeutic follow-up. The pharmacotherapeutic follow-up is fundamental for the improvement of patient's health. New studies, with higher number of patients and longer duration, are necessary to evaluate the percentage of patients that could be beneficiary of Pharmaceutical Care.

Language: en

Keywords

adult; human; female; male; bipolar disorder; pilot study; comorbidity; clozapine; Pharmacotherapy; mood disorder; obesity; levothyroxine; article; clinical article; amfebutamone; citalopram; fluoxetine; lithium carbonate; acetylsalicylic acid; haloperidol; paracetamol; follow up; carbamazepine; olanzapine; risperidone; pharmaceutical care; Hamilton scale; biperiden; unindexed drug; valproic acid; hypertension; lamotrigine; topiramate; cimetidine; propranolol; clonazepam; insulin; sulpiride; hypothyroidism; atenolol; metformin; Pharmaceutical care; omeprazole; norfloxacin; doxazosin; amlodipine; carisoprodol; Young Mania Rating Scale; ipratropium bromide; Bipolar mood disorder